<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="/static/rendered_html/uslm.css">
        <link rel="stylesheet" href="/static/rendered_html/style.css">
        <script src="https://kit.fontawesome.com/2ce1080035.js" crossorigin="anonymous"></script>
        <script lang="text/javascript" src="/static/rendered_html/omni.js" defer></script>

        <!-- Table of Contents button section sheet. Would ideally be a working breadcrumb --> 
        <img src="../omni.jpg" alt="Omnibuster" style="width:100%">
        <ul class="breadcrumb" style="text-align:center">
            <!-- TODO GENERALIZE THIS --> 
            <li><a href="index.html"> Table of Contents</a></li>
            
                <li> Division A </a></li>
            
                <li> Title III </a></li>
            
                <li> Subtitle A </a></li>
            
                <li> Part I </a></li>
            
                <li> Subpart B </a></li>
            
                <li> Section 3112 </a></li>
            
        </ul>


        <!-- <title> Omnibuster </title>
 -->
    </head>

    <body>
        <br><br><br>
        <div class="section">
            <div class="buttons">
                <div class="navbar">
                    <div>
                        <button onclick="highlightSelection();">Highlight Text</button>
                    </div>
                    <div>
                        <div id="textAreaDiv">
                            <textarea name='message' id='message_box'></textarea>
                            <input name='receiver_id' type='text' id='number' style="display: none" value="">
                            <button id='btn' class='btn btn-primary' type='submit'>Add Annotation</button>
                        </div>
                    </div> 
                </div>
            </div>
            <p> 
                <section id="d3355e13309" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112" style="-uslm-lc:I650144"><num value="3112">SEC. 3112. </num><heading>ADDITIONAL MANUFACTURER REPORTING REQUIREMENTS IN RESPONSE TO DRUG SHORTAGES.</heading><subsection class="indent0 fontsize10" id="d3355e13314" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/a" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="a">(a) </num><heading><inline class="small-caps">Expansion To Include Active Pharmaceutical Ingredients</inline>.—</heading><chapeau>Subsection (a) of section 506C of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section356c&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s356c">21 U.S.C. 356c</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="indent1 fontsize10" id="d3355e13329" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/a/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><content>in paragraph (1)(C), by <amendingAction type="insert">inserting</amendingAction> “<quotedText>or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 319 of the Public Health Service Act</quotedText>” after “<quotedText>during surgery</quotedText>”; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13339" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/a/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>in the flush text at the end—</chapeau><subparagraph class="indent2 fontsize10" id="d3355e13344" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/a/2/A" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">(A) </num><content>by <amendingAction type="insert">inserting</amendingAction> “<quotedText>, or a permanent discontinuance in the manufacture of an active pharmaceutical ingredient or an interruption in the manufacture of the active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug,</quotedText>” before “<quotedText>and the reasons</quotedText>”; and</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" id="d3355e13354" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/a/2/B" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">(B) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following: “<quotedText>Notification under this subsection shall include disclosure of reasons for the discontinuation or interruption, and if applicable, an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation or interruption, the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation or interruption; the expected duration of the interruption; and such other information as the Secretary may require.</quotedText>”.</content>
</subparagraph>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13366" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/b" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="b">(b) </num><heading><inline class="small-caps">Risk Management</inline>.—</heading><content>Section 506C of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section356c&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s356c">21 U.S.C. 356c</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="j">“(j) </num><heading><inline class="small-caps">Risk Management Plans</inline>.—</heading><content>Each manufacturer of a drug described in subsection (a) or of any active pharmaceutical ingredient or any associated medical device used for preparation or administration included in the drug, shall develop, maintain, and implement, as appropriate, a redundancy risk management plan that identifies and evaluates risks to the supply of the drug, as applicable, for each establishment in which such drug or active pharmaceutical ingredient of such drug is manufactured. A risk management plan under this section shall be subject to inspection and copying by the Secretary pursuant to an inspection or a request under section 704(a)(4).”</content>
</subsection>
</quotedContent>.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13399" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/c" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="c">(c) </num><heading><inline class="small-caps">Annual Notification</inline>.—</heading><content>Section 506E of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section356e&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s356e">21 U.S.C. 356e</ref></a>) <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subsection class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">“(d) </num><heading><inline class="small-caps">Interagency Notification</inline>.—</heading><content>Not later than 180 days after the date of enactment of this subsection, and every 90 days thereafter, the Secretary shall transmit a report regarding the drugs of the current drug shortage list under this section to the Administrator of the Centers for Medicare &amp; Medicaid Services.”</content>
</subsection>
</quotedContent>.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13432" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/d" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="d">(d) </num><heading><inline class="small-caps">Reporting After Inspections</inline>.—</heading><chapeau>Section 704(b) of the Federal Food, Drug, and Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section374&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s374/b">21 U.S.C. 374(b)</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="indent1 fontsize10" id="d3355e13447" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/d/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> paragraphs (1) and (2) and subparagraphs (A) and (B);</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13457" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/d/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>(b) Upon completion</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>(b)(1) Upon completion</quotedText>”; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13470" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/d/3" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">(3) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><paragraph class="indent0 fontsize10" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="2">“(2) </num><content>In carrying out this subsection with respect to any establishment manufacturing a drug approved under subsection (c) or (j) of section 505 for which a notification has been submitted in accordance with section 506C is, or has been in the last 5 years, listed on the drug shortage list under section 506E, or that is described in section 505(j)(11)(A), a copy of the report shall be sent promptly to the appropriate offices of the Food and Drug Administration with expertise regarding drug shortages.”</content>
</paragraph>
</quotedContent>.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13490" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/e" role="instruction" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="e">(e) </num><heading><inline class="small-caps">Reporting Requirement</inline>.—</heading><chapeau>Section 510(j) of the Federal Food, Drug, Cosmetic Act (<a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t21/s360/j">21 U.S.C. 360(j)</ref></a>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="indent1 fontsize10" id="d3355e13505" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/e/1" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> paragraphs (3) and (4) as paragraphs (4) and (5), respectively; and</content>
</paragraph>
<paragraph class="indent1 fontsize10" id="d3355e13515" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/e/2" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="insert">inserting</amendingAction> after paragraph (2) the following:<quotedContent><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="3">“(3)</num><subparagraph class="inline"><num value="A">(A) </num><content>Each person who registers with the Secretary under this section with regard to a drug shall report annually to the Secretary on the amount of each drug listed under paragraph (1) that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution. Such information may be required to be submitted in an electronic format as determined by the Secretary. The Secretary may require that information required to be reported under this paragraph be submitted at the time a public health emergency is declared by the Secretary under section 319 of the Public Health Service Act.</content>
</subparagraph>
<subparagraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>By order of the Secretary, certain biological products or categories of biological products regulated under section 351 of the Public Health Service Act may be exempt from some or all of the reporting requirements under subparagraph (A), if the Secretary determines that applying such reporting requirements to such biological products or categories of biological products is not necessary to protect the public health.”</content>
</subparagraph>
</paragraph>
</quotedContent>.</content>
</paragraph>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13547" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/f" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="f">(f) </num><heading><inline class="small-caps">Confidentiality</inline>.—</heading><content>Nothing in the amendments made by this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title5-section552&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t5/s552/b/4">section 552(b)(4) of title 5, United States Code</ref></a>, or <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section1905&amp;num=0&amp;edition=prelim" target="_blank"><ref href="/us/usc/t18/s1905">section 1905 of title 18, United States Code</ref></a>.</content>
</subsection>
<subsection class="indent0 fontsize10" id="d3355e13564" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptI/sptB/s3112/g" style="-uslm-lc:I650120"><num style="-uslm-lc:emspace2" value="g">(g) </num><heading><inline class="small-caps">Effective Date</inline>.—</heading><content>The amendments made by this section and section 3111 shall take effect on the date that is 180 days after the date of enactment of this Act.</content>
</subsection>
</section>
            </p>
        </div>  

        <!-- previous section -->
        <button onclick="location.href='section_s3111.html'" id="ls-btn-prev-sec" title="go to previous section">
            <i class="fas fa-angle-left"></i>
        </button>
        <!-- end previous section -->

        <!-- next section -->
        <button onclick="location.href='section_s3121.html'" id="ls-btn-next-sec" title="go to next section" data-ls-target-index="2">
            <i class="fas fa-angle-right"></i>
        </button>
        <!-- end next section -->

    </body>
